GLP-1 drugs linked to reduced cancer risk, researchers say
GLP-1 drugs, primarily used for weight loss and diabetes, are associated with reduced cancer risk, including for breast, colon, pancreatic, and liver cancers. Researchers suggest this may be due to weight loss and anti-inflammatory effects, but emphasize more studies are needed to confirm causality.
Mentioned
Related Signal
Adjacent reporting
- GLP-1 drugs may reduce the risk of cancer progressing, study suggests
- Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk
- GLP-1 drugs linked to major slowdown in breast cancer, prostate cancer and more: new study
- GLP-1 weight-loss drugs might help protect against breast cancer, study presented at ASCO meeting suggests
- GLP-1s appear to protect against cancer. Researchers are trying to figure out how